Advertisement
U.S. markets closed

Affimed N.V. (AFMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.30-0.03 (-0.56%)
At close: 04:00PM EDT
5.30 +0.00 (+0.02%)
After hours: 07:09PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close5.33
Open5.33
Bid5.26 x 100
Ask5.36 x 200
Day's Range5.11 - 5.43
52 Week Range2.24 - 11.10
Volume80,699
Avg. Volume92,107
Market Cap79.15M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-8.56
Earnings DateMay 21, 2024 - May 27, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AFMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Affimed N.V.
    XNCR: Rating increased to a HOLDXENCOR INC has an Investment Rating of HOLD; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Affimed Reports 2023 Financial Results and Operational Progress

    AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and initial efficacy data from the EGFR-mutant NSCLC cohorts are expected in Q2 2024.A

  • GlobeNewswire

    Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

    MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be a

  • Zacks

    Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know

    Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.